PharmTech Drug Digest 11.20
News|Articles|May 17, 2018

Catalent Adds Capacity at Kansas City Clinical Supplies Facility

The second phase of a $5.5-million expansion adds controlled-substance and controlled-temperature storage to Catalent clinical trials facility.

Catalent Pharma Solutions announced on May 17, 2018 the completion of the second phase of a $5.5-million expansion program at its Kansas City, MO facility, which increased the controlled-substance and controlled-temperature storage capabilities for its clinical supply business.

The expansion included a Drug Enforcement Administration Schedule I and II controlled substance vault; 3600-sq.-ft. of additional storage; controlled-temperature storage capacity with 450 new pallet locations and 500 new high-density storage locations; a sampling room; and an emergency generator.

The 450,000-sq.-ft. facility provides development and analytical support through to packaging and distribution, the company reported in a press statement. Previously, the company announced expansions at clinical supply facilities in Philadelphia and Singapore.

Source: Catalent Pharma Solutions

 

 


Related to this article

Green Chemistry Supply and Demand in Sustainable Pharma
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.